Last reviewed · How we verify
CD22CART cell infusion
At a glance
| Generic name | CD22CART cell infusion |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies (PHASE1)
- Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (PHASE1)
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |